α-synuclein degradation by autophagic pathways: A potential key to Parkinson's disease pathogenesis

Autophagy

Volumn 4, Issue 7, 2008, Pages 917-919

  Xilouri, Maria ^a   Vogiatzi, Tereza ^a   Vekrellis, Kostas ^a   Stefanis, Leonidas ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alpha synuclein; Autophagy; Macroautophagy; Neurons; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; CHAPERONE; MESSENGER RNA;

AGING; ANIMAL CELL; ARTICLE; AUTOPHAGY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; LYSOSOME; NERVE CELL; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN DEGRADATION;

EID: 53549118274     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.6685     Document Type: Article

References (26)

1. Vekrellis K, Rideout HJ, Stefanis L. Neurobiology of alpha-synuclein. Mol Neurobiol 2004; 30:1-21.
2. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302:841.
3. Bennett MC, Bishop JF, Leng Y, et al. Degradation of α-synuclein by proteasome. J Biol Chem 1999; 274:33855-8.
4. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 2002; 111:209-18.
5. Tofaris GK, Layfield R, Spillantini MG. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 2001; 509:22-6.
6. Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001; 78:899-908.
7. Rideout HJ, Stefanis L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 2002; 21:223-38.
8. Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging 2008; in press.
9. Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305:1292-5.
10. Massey AC, Kaushik S, Sovak G, et al. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci USA 2006; 103:5805-10.
11. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type α-synuclein is degraded by chaperone-mediated autophagyand macroautophagy in neuronal cells. J Biol Chem 2008; 283:23542-56.
12. Webb JL, Ravikumar B, Atkins J, et al. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003; 278:25009-13.
13. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis 2007; 25:134-49.
14. Li W, Lesuisse C, Xu Y, et al. Stabilization of alpha-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J Neurosci 2004; 24:7400-9.
15. Chu Y, Le W, Kompoliti K, et al. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006; 494:495-514.
16. Petersen K, Olesen OF, Mikkelsen JD. Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 1999; 91:651-9.
17. Malarynska E, Pinhasov A, Crooke J, et al. Levels of mRNA coding for alpha-, beta-, and gamma-synuclein in the brains of newborn, juvenile, and adult rats. J Mol Neurosci 2006; 29:269-77.
18. Kingsbury AE, Daniel SE, Sangha H, et al. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov Disord 2004; 19:162-70.
19. Grundemann J, Schlaudraff F, Haeckel O, Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 2008; 36:38.
20. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441:880-4.
21. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441:885-9.
22. Massey AC, Zhang C, Cuervo AM. Chape rone-mediated autophagy in aging and disease. Curr Top Dev Biol 2006; 73:205-35.
23. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest; 2008; 118:777-88.
24. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351:1972-7.
25. Di Fonzo A, Chien HF, Socal M, et al. ATP13A2 missense mutations in juvenile Parkinsonism and young onset Parkinson disease. Neurology 2007; 68:1557-62.
26. Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21:9549-60.